Chart review reveals how CML patients fare on standard therapy
NCT ID NCT00816114
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviews medical charts of up to 3,000 chronic myelogenous leukemia (CML) patients who received standard tyrosine kinase inhibitors like imatinib outside of a clinical trial. Researchers want to understand real-world treatment patterns, responses, side effects, and pregnancy outcomes. No new drug is being tested; the goal is to gather knowledge from routine care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World check: does bosutinib control CML safely?
- New transplant recipe aims to tame Graft-Versus-Host disease
- Suicide Gene-Equipped t cells aim to make stem cell transplants safer
- New drug combo aims to make stem cell transplants safer for blood cancer patients
- New stem cell method shows promise for young blood cancer patients
- Cord blood transplant offers hope for young blood cancer patients